Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,077,142
  • Shares Outstanding, K 62,377
  • Annual Sales, $ 814,760 K
  • Annual Income, $ -258,000 K
  • EBIT $ -154 M
  • EBITDA $ -134 M
  • 60-Month Beta 0.49
  • Price/Sales 17.86
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 50.39% (-1.02%)
  • Historical Volatility 36.21%
  • IV Percentile 62%
  • IV Rank 39.01%
  • IV High 70.31% on 08/01/25
  • IV Low 37.64% on 06/16/25
  • Expected Move (DTE 7) 9.26 (3.87%)
  • Put/Call Vol Ratio 2.46
  • Today's Volume 1,445
  • Volume Avg (30-Day) 613
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 20,612
  • Open Int (30-Day) 18,663
  • Expected Range 230.02 to 248.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.30
  • Number of Estimates 7
  • High Estimate $0.81
  • Low Estimate $-0.24
  • Prior Year $-1.66
  • Growth Rate Est. (year over year) +118.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
212.60 +12.55%
on 03/24/26
246.76 -3.03%
on 04/09/26
-1.24 (-0.52%)
since 03/10/26
3-Month
188.08 +27.22%
on 01/12/26
248.60 -3.75%
on 03/03/26
+36.29 (+17.88%)
since 01/09/26
52-Week
142.18 +68.29%
on 04/11/25
248.60 -3.75%
on 03/03/26
+95.95 (+66.94%)
since 04/10/25

Most Recent Stories

More News
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

 - Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs)  - ADS holders will receive one ordinary share listed on Nasdaq...

ASND : 239.28 (-1.01%)
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia

- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community - Enhanced improvements in spinal...

ASND : 239.28 (-1.01%)
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially...

ASND : 239.28 (-1.01%)
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children  - TransCon hGH showed a safety and tolerability...

ASND : 239.28 (-1.01%)
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

COPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with...

ASND : 239.28 (-1.01%)
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference

COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual...

ASND : 239.28 (-1.01%)
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing interval Commercial availability expected during early part of Q2 2026 Rare...

ASND : 239.28 (-1.01%)
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 million Q4 2025 operating profit of €10 million and cash flow from operating activities of €73 million TransCon...

ASND : 239.28 (-1.01%)
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday,...

ASND : 239.28 (-1.01%)
Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026

Investing in these three biotech stocks can offer investors with a high-risk profile the opportunity to generate outsized gains over the next decade.

LGND : 204.92 (-0.35%)
KNSA : 47.08 (-0.53%)
ASND : 239.28 (-1.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

3rd Resistance Point 248.01
2nd Resistance Point 244.86
1st Resistance Point 242.07
Last Price 239.28
1st Support Level 236.13
2nd Support Level 232.98
3rd Support Level 230.19

See More

52-Week High 248.60
Last Price 239.28
Fibonacci 61.8% 207.95
Fibonacci 50% 195.39
Fibonacci 38.2% 182.83
52-Week Low 142.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.